PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀
September 19, 2023 07:00 ET
|
PolyPid Ltd.
Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale Completes a Substantial Requirement Toward the Planned Submission of D-PLEX100 NDA and MAA...
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 09, 2023 07:00 ET
|
PolyPid Ltd.
Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase...
PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023
July 26, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, July 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections
June 29, 2023 08:00 ET
|
PolyPid Ltd.
Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide Range of Bacteria Tested, including Resistant Strains D-PLEX100 Antibacterial Activity Attributed to...
PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
June 22, 2023 07:00 ET
|
PolyPid Ltd.
Company Recently Reached Agreement with FDA on Design of Trial Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq:...
PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market
June 05, 2023 16:02 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, June 05, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
May 22, 2023 09:00 ET
|
PolyPid Ltd.
Recruitment to Resume Imminently Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, May 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a...
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 10, 2023 07:00 ET
|
PolyPid Ltd.
Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections; Recruitment Expected to Resume Imminently Received...
PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023
April 26, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid to Participate in Upcoming Investor Conferences
April 24, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...